Search Results - "Adamkewicz, Joanne"

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays by Adamkewicz, Joanne I, Chen, David C, Paz-Priel, Ido

“…Emicizumab bridges activated factor IX (FIX) and FX to restore the tenase function mediated by activated FVIII (FVIIIa), which is deficient in people with…”
Get more information

Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer by Marshall, Derek C, Lyman, Susan K, McCauley, Scott, Kovalenko, Maria, Spangler, Rhyannon, Liu, Chian, Lee, Michael, O'Sullivan, Christopher, Barry-Hamilton, Vivian, Ghermazien, Haben, Mikels-Vigdal, Amanda, Garcia, Carlos A, Jorgensen, Brett, Velayo, Arleene C, Wang, Ruth, Adamkewicz, Joanne I, Smith, Victoria

“…Expression of matrix metalloproteinase 9 (MMP9) is elevated in a variety of inflammatory and oncology indications, including ulcerative colitis and colorectal…”
Get full text

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors by Mahlangu, Johnny, Oldenburg, Johannes, Paz-Priel, Ido, Negrier, Claude, Niggli, Markus, Mancuso, M. Elisa, Schmitt, Christophe, Jiménez-Yuste, Victor, Kempton, Christine, Dhalluin, Christophe, Callaghan, Michael U, Bujan, Willem, Shima, Midori, Adamkewicz, Joanne I, Asikanius, Elina, Levy, Gallia G, Kruse-Jarres, Rebecca

“…Emicizumab binds to activated factor IX and factor X, reproducing the bridging function of the missing factor VIII. In a trial of emicizumab prophylaxis,…”
Get full text

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study by Kiialainen, Anna, Niggli, Markus, Kempton, Christine L., Castaman, Giancarlo, Chang, Tiffany, Paz‐Priel, Ido, Adamkewicz, Joanne I., Levy, Gallia G.

“…Introduction Emicizumab prophylaxis significantly reduces bleeding events; however, the associated impact on bone/joint health is unknown. Aim To explore the…”
Get full text

Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment by Yang, Jin, Savvatis, Konstantinos, Kang, Jong Seok, Fan, Peidong, Zhong, Hongyan, Schwartz, Karen, Barry, Vivian, Mikels-Vigdal, Amanda, Karpinski, Serge, Kornyeyev, Dmytro, Adamkewicz, Joanne, Feng, Xuhui, Zhou, Qiong, Shang, Ching, Kumar, Praveen, Phan, Dillon, Kasner, Mario, López, Begoña, Diez, Javier, Wright, Keith C., Kovacs, Roxanne L., Chen, Peng-Sheng, Quertermous, Thomas, Smith, Victoria, Yao, Lina, Tschöpe, Carsten, Chang, Ching-Pin

“…Interstitial fibrosis plays a key role in the development and progression of heart failure. Here, we show that an enzyme that crosslinks collagen—Lysyl…”
Get full text

SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment by Sodir, Nicole M, Pathria, Gaurav, Adamkewicz, Joanne I, Kelley, Elizabeth H, Sudhamsu, Jawahar, Merchant, Mark, Chiarle, Roberto, Maddalo, Danilo

“…The protein phosphatase SHP2/PTPN11 has been reported to be a key modulator of proliferative pathways in a wide range of malignancies. Intriguingly, SHP2 has…”
Get more information

Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure by Karsdal, Morten A, Nielsen, Mette J, Sand, Jannie M, Henriksen, Kim, Genovese, Federica, Bay-Jensen, Anne-Christine, Smith, Victoria, Adamkewicz, Joanne I, Christiansen, Claus, Leeming, Diana J

“…Increased attention is paid to the structural components of tissues. These components are mostly collagens and various proteoglycans. Emerging evidence…”
Get more information

Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays by Adamkewicz, Joanne I., Kiialainen, Anna, Paz‐Priel, Ido

Get full text

High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888 by Lyman, Susan K, Crawley, Suzanne C, Gong, Ruoyu, Adamkewicz, Joanne I, McGrath, Garth, Chew, Jason Y, Choi, Jennifer, Holst, Charles R, Goon, Leanne H, Detmer, Scott A, Vaclavikova, Jana, Gerritsen, Mary E, Blake, Robert A

“…Many proteins that are dysregulated or mutated in cancer cells rely on the molecular chaperone HSP90 for their proper folding and activity, which has led to…”
Get full text

Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks by Kiialainen, Anna, Adamkewicz, Joanne I., Petry, Claire, Oldenburg, Johannes, Pipe, Steven W., Young, Guy, Mahlangu, Johnny, Lehle, Michaela, Niggli, Markus, Castaman, Giancarlo, Jiménez-Yuste, Víctor, Shima, Midori, Négrier, Claude, Schmitt, Christophe

“…Emicizumab is a bispecific antibody that bridges activated factor (F)IX and FX, mimicking the function of missing activated FVIII and thus improving hemostasis…”
Get full text

Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression by CHIEN, Jason W, RICHARDS, Thomas J, O'RIORDAN, Thomas, GIBSON, Kevin F, YINGZE ZHANG, LINDELL, Kathleen O, LIXIN SHAO, LYMAN, Susan K, ADAMKEWICZ, Joanne I, SMITH, Victoria, KAMINSKI, Naftali

“…We evaluated whether lysyl oxidase-like 2 (LOXL2), which promotes cross-linking of collagen in pathological stroma, was detectable in serum from idiopathic…”
Get full text

Correction: High-Content, High-Throughput Analysis of Cell Cycle Perturbations Induced by the HSP90 Inhibitor XL888 by Lyman, Susan K., Crawley, Suzanne C., Gong, Ruoyu, Adamkewicz, Joanne I., McGrath, Garth, Chew, Jason Y., Choi, Jennifer, Holst, Charles R., Goon, Leanne H., Detmer, Scott A., Vaclavikova, Jana, Gerritsen, Mary E., Blake, Robert A.

“…Jennifer Choi and Jana Vaclavikova are solely affiliated with: "Department of Genome Biology, Exelixis, Inc., South San Francisco, California, United States of…”
Get full text

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3 by Kiialainen, Anna, Niggli, Markus, Kempton, Christine L., Castaman, Giancarlo, Chang, Tiffany Y., Paz-Priel, Ido, Adamkewicz, Joanne I, Levy, Gallia G.

“…Introduction Emicizumab is a recombinant, humanized, bispecific monoclonal antibody that restores the function of missing activated factor VIII (FVIII) by…”
Get full text

Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis by Pollheimer, Marion J., Racedo, Silvia, Mikels-Vigdal, Amanda, Marshall, Derek, Bowlus, Christopher, Lackner, Carolin, Madl, Tobias, Karlsen, Tom H., Hov, Johannes R., Lyman, Susan K., Adamkewicz, Joanne, Smith, Victoria, Moreau, Emmanuel, Zollner, Gernot, Eide, Tor Jacob, Stojakovic, Tatjana, Scharnagl, Hubert, Gruber, Hans-Jürgen, Stauber, Rudolf E., Trauner, Michael, Fickert, Peter

“…[Display omitted] •Cellular senescence triggers LOXL2-expression and E-cadherin downregulation, reducing transepithelial resistance in BECS.•Mouse models of…”
Get full text

Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study by Callaghan, Michael U., Negrier, Claude, Young, Guy, Khoo, Liane, Mahlangu, Johnny, Windyga, Jerzy, Oldenburg, Johannes, Xu, Jin, Catalani, Olivier, Asikanius, Elina, Adamkewicz, Joanne I., Shima, Midori

“…Introduction Emicizumab, a bispecific humanized monoclonal antibody in development for the management of patients (pts) with hemophilia A (PwHA) with/without…”
Get full text

High Affinity Interaction of Yeast Transcriptional Regulator, Mot1, with TATA Box-binding Protein (TBP) by Adamkewicz, Joanne I., Hansen, Karin E., Prud'homme, Wendy A., Davis, Jennifer L., Thorner, Jeremy

“…Yeast Mot1, an essential ATP-dependent regulator of basal transcription, removes TATA box-binding protein (TBP) from TATA sites in vitro. Complexes of Mot1 and…”
Get full text

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma by Raval, Aparna, Cho, Hearn Jay, Green, Cherie, Wassner Fritsch, Elisabeth, Ma, Connie, Chang, Naomi, Yan, Mark, Kockx, Mark, Shen, Shine, Huw, Ling-Yuh, Balestiere, Emily, Lipkind, Marina, Huang, Huang, Byrtek, Michelle, Colburn, Dawn, Wong, Sandy W., Venstrom, Jeffrey M., Adamkewicz, Joanne I

“…Introduction: Immune checkpoint inhibition targeting the PD-1/PD-L1 pathway is insufficient to induce clinical response in relapsed or refractory (R/R)…”
Get full text

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma by Hernandez, Genevive, Huw, Ling-Yuh, Belousov, Anton, Wilson, Deanna, Koeppen, Hartmut, McCord, Ron, Peng, Kun, Bartlett, Nancy L, Budde, Lihua E, Assouline, Sarit, Nastoupil, Loretta J., Yoon, Dok Hyun, Matasar, Matthew J, Bender, Brendan, Kwan, Antonia, Li, Chi-Chung, O'Hear, Carol, Yin, Shen, Wei, Michael C, Adamkewicz, Joanne I

“…Introduction: Mosunetuzumab (M; RG7828) is a full-length, fully humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both CD3 (on the surface of T…”
Get full text

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma by Li, Chi-Chung, Bender, Brendan, Yin, Shen, Li, Zao, Zhang, Cindy, Hernandez, Genevive, Kwan, Antonia, Sun, Laura, Adamkewicz, Joanne I, Wang, Hong, Dimier, Natalie, Lim, Sue-Zen, O'Hear, Carol, Sehn, Laurie H, Flinn, Ian W., Yoon, Sung-Soo, Budde, Lihua E, Li, Chunze, Wei, Michael C

“…Introduction: Mosunetuzumab (M; RG7828) is a full-length, fully humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both CD3 (on the surface of T…”
Get full text

Distinct Patterns of PD-L1 and PD-L2 Expression By Tumor and Non-Tumor Cells in Patients with MM, MDS and AML by Dail, Monique, Yang, Long, Green, Cherie, Ma, Connie, Robert, Alberto, Kadel, Edward E., Koeppen, Harmut, Adamkewicz, Joanne, Byon, John, Woodard, Joseph, Rodig, Scott J, Venstrom, Jeffrey M

“…Introduction:Programmed death-ligand 1 (PD-L1) contributes to tumor escape from immune surveillance by binding to programmed death-1 (PD-1), a negative…”
Get full text